<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967629</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-0976</org_study_id>
    <nct_id>NCT00967629</nct_id>
  </id_info>
  <brief_title>Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy</brief_title>
  <official_title>Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral sevelamer carbonate binds advanced
      glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic
      nephropathy leading to decrease body AGE load and therefore decreases the inflammation and
      oxidative stress in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditional vascular risk factors alone cannot account for the elevated cardiovascular risk
      in patients with chronic kidney disease (CKD). In addition to a high prevalence of
      hypertension and diabetes, patients with CKD have elevated levels of inflammatory markers and
      OS, which are emerging as important risk factors for cardiovascular disease (CVD). Patients
      with CKD are also known to have elevated levels of circulating advanced glycation end
      products (AGE's), which have been shown to induce OS and to play a central role in the
      development of diabetic microvascular and macrovascular complications. In CKD patients, AGE's
      accumulate secondary to decreased renal clearance and increased endogenous production in the
      setting of high levels of OS. Efforts to understand relationships between the multiple
      vascular risk factors in chronic kidney disease may lead to reduced morbidity and mortality
      in this population of patients.

      Sevelamer Hydrochloride is an anion exchange resin composed of multiple positively charged
      amine groups indicated for the treatment of hyperphosphatemia in patients with stage V CKD.
      The positively charged amine groups bind negatively charged dietary phosphate preventing
      systemic absorption. Sevelamer Hydrochloride has been shown to have the added benefits of
      lowering LDL levels, lowering highly sensitive C-reactive protein (hsCRP) levels, and
      improving insulin resistance. Patients treated with Sevelamer Hydrochloride have also been
      shown to have improved vascular compliance and reduced progression of coronary vascular
      calcification. Since AGE's are mostly negatively charged compounds, Sevelamer Carbonate by
      analogy, may have anti-AGE effects which could reduce inflammation and oxidative stress.
      Sevelamer Carbonate would have a major advantage over Calcium Carbonate-based phosphate
      binders, based on the fact that it would have the added advantage of reducing the levels of
      AGEs. The resultant reduction of both OS and inflammation would be expected to have an
      independent beneficial effect on the rate of progression of CKD and CVD.

      We have shown in CKD patients and in animal models that AGE's correlate with levels of OS,
      LDL, hsCRP, and insulin resistance. Additionally, these factors can be remediated in CKD and
      non-CKD diabetics by decreasing overall AGE load, particularly in the diet. To date, the
      effect of Sevelamer Hydrochloride or Sevelamer Carbonate on OS and circulating AGE levels has
      not been studied. The anti-inflammatory and lipid-lowering effects of Sevelamer Hydrochloride
      may occur through lowering serum AGE levels and OS. Sevelamer Carbonate is an improved form
      of Sevelamer Hydrochloride that has been shown to be a safe and effective alternative to
      calcium carbonate in the treatment of hyperphosphatemia in the earlier sta`ges of CKD without
      causing metabolic acidosis. The development of Sevelamer Carbonate provides an opportunity to
      study patients with earlier stages of CKD, and to determine if it prevents or slows the
      progression of CKD. We propose a study designed to compare the effects of calcium carbonate
      and of Sevelamer Carbonate on serum AGE levels and OS in patients with stage II-IV diabetic
      nephropathy.

      Hypothesis:

      Sevelamer Carbonate administration in persons with stage II-IV CKD, compared with calcium
      carbonate administration, will result in at least a:

        1. 20% decrease in serum levels of AGE's;

        2. 10% decease in inflammatory markers of CRP and VCAM-1, or of OS (AGER1/RAGE) in
           circulating mononuclear cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum AGE levels</measure>
    <time_frame>baseline</time_frame>
    <description>To compare the effect of Sevelamer Carbonate versus calcium carbonate on serum AGE levels in patients with stage II-IV chronic kidney disease resulting from diabetic nephropathy from baseline to 2 months and to 4 months later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum AGE levels</measure>
    <time_frame>at 2 months</time_frame>
    <description>To compare the effect of Sevelamer Carbonate versus calcium carbonate on serum AGE levels in patients with stage II-IV chronic kidney disease resulting from diabetic nephropathy from baseline to 2 months and to 4 months later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum AGE levels</measure>
    <time_frame>at 4 months</time_frame>
    <description>To compare the effect of Sevelamer Carbonate versus calcium carbonate on serum AGE levels in patients with stage II-IV chronic kidney disease resulting from diabetic nephropathy from baseline to 2 months and to 4 months later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>baseline</time_frame>
    <description>To compare the effect of sevelamer carbonate versus calcium carbonate on markers of inflammation, oxidative stress, and serum lipid levels in patients with stage II-IV CKD resulting from diabetic nephropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>at 2 months</time_frame>
    <description>To compare the effect of sevelamer carbonate versus calcium carbonate on markers of inflammation, oxidative stress, and serum lipid levels in patients with stage II-IV CKD resulting from diabetic nephropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>at 4 months</time_frame>
    <description>To compare the effect of sevelamer carbonate versus calcium carbonate on markers of inflammation, oxidative stress, and serum lipid levels in patients with stage II-IV CKD resulting from diabetic nephropathy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Carbonate crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.</description>
    <arm_group_label>Sevelamer Carbonate crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.</description>
    <arm_group_label>Calcium Carbonate crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years old

          2. Evidence of CKD II, III or IV Stage II CKD: eGFR 60-89 cc/min Stage III CKD: eGFR
             30-59 cc/min Stage IV CKD: eGFR 15-20 cc/min

          3. Proteinuria on urinalysis on two occasions within 18 months of recruitment

          4. Diagnosis of diabetes and receiving at least one medication for diabetes mellitus.

        Exclusion Criteria:

          1. Age &lt; 18 years old

          2. Stage I and V CKD

          3. Patients receiving active treatment for hyperphosphatemia.

          4. Biopsy proven renal disease other than diabetic nephropathy

          5. Hypophosphatemia

          6. Hypercalcemia

          7. any history of significant gastrointestinal disorders

          8. any history of significant gastrointestinal surgery such as ileostomy, colostomy and
             colectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Vlassara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003 Mar;14(3):728-31.</citation>
    <PMID>12595509</PMID>
  </reference>
  <reference>
    <citation>Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004 Apr;43(4):690-5.</citation>
    <PMID>15042546</PMID>
  </reference>
  <reference>
    <citation>Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004 Aug;104(8):1287-91. Erratum in: J Am Diet Assoc. 2005 Apr;105(4):647.</citation>
    <PMID>15281050</PMID>
  </reference>
  <reference>
    <citation>Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):427-33.</citation>
    <PMID>17452738</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>CKD progression</keyword>
  <keyword>AGEs</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>dietary AGEs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

